With financing from Sweden’s innovation agency (Vinnova), Pharmetheus is increasing its engagement in the development of quantitative approaches to improve chances of clinical success and facilitate risk mitigation in the development of drugs intended for subcutaneous administration. With a combination of quantitative system pharmacology) and physiologically based biopharmaceutics modeling, we aim to achieve quantitative description, translation, and prediction of pharmacological interactions and drug delivery-dependent drug disposition. This will further invigorate our existing commitment in the research forum SweDeliver.
Read more about the project here: https://pharmetheus.com/subq-platform-initiative/
